Generic Name and Formulations:
Erythromycin (as base) 250mg, 333mg, 500mg; e-c tabs.
Arbor Pharmaceuticals, LLC
- Breakthrough Cancer Pain Managed Effectively With Fentanyl Buccal Tablets
- Erythropoietin plus radiation does not improve local-regional control in anemic patients with head and neck cancer
- Olaparib tablet safe in patients with ovarian cancer who received pretreatment
Indications for ERY-TAB:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
250mg every 6 hours, 500mg every 12 hours, or 333mg every 8 hours; max 4g/day; twice daily dosing max 1g/day. Legionnaires: 1–4g/day in divided doses.
30–50mg/kg/day in divided doses; max 100mg/kg/day.
Concomitant cisapride, pimozide.
Hepatic dysfunction. Myasthenia gravis. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP450 (eg, carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, disopyramide, bromocriptine, valproate). May potentiate warfarin, triazolam, midazolam, methylprednisolone, digoxin, theophylline, ergotamine. Avoid use with statins (rhabdomyolysis).
GI upset, abdominal pain, anorexia, hepatic dysfunction, rash, superinfection; pseudomembranous colitis, (rare).
250mg—30, 40, 100, 500; 333mg—30, 100, 500; 500mg—100
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|